Shilpa Medicare launches 'IBRUSHIL' for the treatment of Leukemia

28 May 2020 Evaluate
Shilpa Medicare has launched the Indian branded generic of Ibrutinib, an anti-cancer drug with a brand name IBRUSHIL. IBRUSHIL is available in 140 mg capsules in packs of 30's capsules and 120's capsules. IBRUSHIL is used to treat patients suffering from Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphomas (MCL) and other related cancers.

This new Leukemia drug is more effective and easier to use. IBRUSHIL attacks cancer cells without damaging normal cells, this causing fewer side effects. The drug is taken once daily, than the standard treatment that requires multiple injections by the patients. Current, monthly therapy cost of innovator is approximately Rs 4.36 Lacs, with the launch of IBRUSHIL monthly cost of treatment will be reduced drastically to Rs 34,920, as monthly therapy cost.

IBRUSHIL (Ibrutinib 140 mg) capsules is being manufactured in the state-of-the-art US Food and Drug Administration (US FDA) approved manufacturing facility. IBRUSHIL is the same product which was filed with US FDA thus Shilpa is bringing a quality product meeting the world class standards.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

322.25 -2.70 (-0.83%)
18-Dec-2025 12:34 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1745.00
Dr. Reddys Lab 1277.80
Cipla 1504.70
Zydus Lifesciences 915.85
Lupin 2121.90
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×